Issue

Vol. 13 (2021)

Nanoplatforms for Sepsis Management: Rapid Detection/Warning, Pathogen Elimination and Restoring Immune Homeostasis

https://doi.org/10.1007/s40820-021-00598-3
Gan Luo
Department of Anesthesiology and Intensive Care, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, People’s Republic of China
Jue Zhang
Department of Anesthesiology and Intensive Care, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, People’s Republic of China
Yaqi Sun
Department of Anesthesiology and Intensive Care, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, People’s Republic of China
Ya Wang
Department of Anesthesiology and Intensive Care, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, People’s Republic of China
Hanbin Wang
Department of Anesthesiology and Intensive Care, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, People’s Republic of China
Baoli Cheng
Department of Anesthesiology and Intensive Care, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, People’s Republic of China
Qiang Shu
National Clinical Research Center for Child Health, Children’s Hospital, School of Medicine, Zhejiang University, Hangzhou 310052, People’s Republic of China
Xiangming Fang
Department of Anesthesiology and Intensive Care, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, People’s Republic of China

Corresponding Author: Xiangming Fang

xmfang@zju.edu.cn

Nano-Micro Letters, Vol. 13 (2021), Article Number: 88

Abstract

Sepsis, a highly life-threatening organ dysfunction caused by uncontrollable immune responses to infection, is a leading contributor to mortality in intensive care units. Sepsis-related deaths have been reported to account for 19.7% of all global deaths. However, no effective and specific therapeutic for clinical sepsis management is available due to the complex pathogenesis. Concurrently eliminating infections and restoring immune homeostasis are regarded as the core strategies to manage sepsis. Sophisticated nanoplatforms guided by supramolecular and medicinal chemistry, targeting infection and/or imbalanced immune responses, have emerged as potent tools to combat sepsis by supporting more accurate diagnosis and precision treatment. Nanoplatforms can overcome the barriers faced by clinical strategies, including delayed diagnosis, drug resistance and incapacity to manage immune disorders. Here, we present a comprehensive review highlighting the pathogenetic characteristics of sepsis and future therapeutic concepts, summarizing the progress of these well-designed nanoplatforms in sepsis management and discussing the ongoing challenges and perspectives regarding future potential therapies. Based on these state-of-the-art studies, this review will advance multidisciplinary collaboration and drive clinical translation to remedy sepsis.


Highlights:


1 This review highlights pathogenesis and clinical challenges of sepsis.
2 Advantages of different types of nanoplatforms are presented, and the rationality of nanoplatforms in sepsis management is analyzed.
3 Advances of nanoplatforms in diagnosis and therapy of sepsis are systematically summarized, and ongoing challenges and future perspectives are discussed.

Keywords

Sepsis Nanoplatform Detection Immune homeostasis
Luo, Gan, Jue Zhang, Yaqi Sun, Ya Wang, Hanbin Wang, Baoli Cheng, Qiang Shu, and Xiangming Fang. 2021. “Nanoplatforms for Sepsis Management: Rapid Detection/Warning, Pathogen Elimination and Restoring Immune Homeostasis”. Nano-Micro Letters 13 (March):88. https://doi.org/10.1007/s40820-021-00598-3.
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. M. Singer, C.S. Deutschman, C.W. Seymour, M. Shankar-Hari, D. Annane et al., The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315(8), 801–810 (2016). https://doi.org/10.1001/jama.2016.0287
  2. C. Fleischmann, A. Scherag, N.K. Adhikari, C.S. Hartog, T. Tsaganos et al., International forum of acute care. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am. J. Resp. Care 193(3), 259–272 (2016). https://doi.org/10.1164/rccm.201504-0781OC
  3. D.C. Angus, W.T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo et al., Epidemiology of severe sepsis in the united states: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29(7), 1303–1310 (2001). https://doi.org/10.1097/00003246-00107000-00002
  4. F.B. Mayr, S. Yende, D.C. Angus, Epidemiology of severe sepsis. Virulence 5(1), 4–11 (2014). https://doi.org/10.4161/viru.27372
  5. D.J. Funk, J.E. Parrillo, A. Kumar, Sepsis and septic shock: a history. Crit. Care Clin. 25(1), 83–101 (2009). https://doi.org/10.1016/j.ccc.2008.12.003
  6. SCCM, American college of chest physicians/society of critical care medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 20(6), 864–874 (1992). https://doi.org/10.1097/00003246-199206000-00025
  7. M.M. Levy, M.P. Fink, J.C. Marshall, E. Abraham, D. Angus et al., 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit. Care Med. 31(4), 1250–1256 (2003). https://doi.org/10.1097/01.CCM.0000050454.01978.3B
  8. V. Liu, G.J. Escobar, J.D. Greene, J. Soule, A. Whippy et al., Hospital deaths in patients with sepsis from 2 independent cohorts. JAMA 312(1), 90–92 (2014). https://doi.org/10.1001/jama.2014.5804
  9. W.T. Linde-Zwirble, D.C. Angus, Severe sepsis epidemiology: Sampling, selection, and society. Crit. Care 8(4), 222–226 (2004). https://doi.org/10.1186/cc2917
  10. M. Cecconi, L. Evans, M. Levy, A. Rhodes, Sepsis and septic shock. Lancet 392(10141), 75–87 (2018). https://doi.org/10.1016/s0140-6736(18)30696-2
  11. B. Cheng, G. Xie, S. Yao, X. Wu, Q. Guo et al., Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in china. Crit. Care Med. 35(11), 2538–2546 (2007). https://doi.org/10.1097/01.CCM.0000284492.30800.00
  12. K.E. Rudd, S.C. Johnson, K.M. Agesa, K.A. Shackelford, D. Tsoi et al., Global, regional, and national sepsis incidence and mortality, 1990–2017: Analysis for the global burden of disease study. Lancet 395(10219), 200–211 (2020). https://doi.org/10.1016/s0140-6736(19)32989-7
  13. T. van der Poll, F.L. van de Veerdonk, B.P. Scicluna, M.G. Netea, The immunopathology of sepsis and potential therapeutic targets. Nat. Rev. Immunol. 17(7), 407–420 (2017). https://doi.org/10.1038/nri.2017.36
  14. M.P. Fink, H.S. Warren, Strategies to improve drug development for sepsis. Nat. Rev. Drug Discov. 13(10), 741–758 (2014). https://doi.org/10.1038/nrd4368
  15. K.N. Iskander, M.F. Osuchowski, D.J. Stearns-Kurosawa, S. Kurosawa, D. Stepien et al., Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Phys. Rev. 93(3), 1247–1288 (2013). https://doi.org/10.1152/physrev.00037.2012
  16. R.S. Hotchkiss, L.L. Moldawer, S.M. Opal, K. Reinhart, I.R. Turnbull et al., Sepsis and septic shock. Nat. Rev. Dis. Primers 2(1), 16045 (2016). https://doi.org/10.1038/nrdp.2016.45
  17. F. Venet, G. Monneret, Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat. Rev. Nephrol. 14(2), 121–137 (2018). https://doi.org/10.1038/nrneph.2017.165
  18. J.C. Marshall, Why have clinical trials in sepsis failed? Trends Mol. Med. 20(4), 195–203 (2014). https://doi.org/10.1016/j.molmed.2014.01.007
  19. J.L. Halbach, A.W. Wang, D. Hawisher, D.M. Cauvi, R.E. Lizardo et al., Why antibiotic treatment is not enough for sepsis resolution: an evaluation in an experimental animal model. Infect. Immun. 85(12), e0066400617 (2017). https://doi.org/10.1128/IAI.00664-17
  20. J.C. Hou, Q. Chen, K. Zhang, B.L. Cheng, G.H. Xie et al., Sphingosine 1-phosphate receptor 2 signaling suppresses macrophage phagocytosis and impairs host defense against sepsis. Anesthesiology 123(2), 409–422 (2015). https://doi.org/10.1097/ALN.0000000000000725
  21. F. Song, J. Hou, Z. Chen, B. Cheng, R. Lei et al., Sphingosine-1-phosphate receptor 2 signaling promotes caspase-11-dependent macrophage pyroptosis and worsens escherichia coli sepsis outcome. Anesthesiology 129(2), 311–320 (2018). https://doi.org/10.1097/ALN.0000000000002196
  22. F. Niessen, F. Schaffner, C. Furlan-Freguia, R. Pawlinski, G. Bhattacharjee et al., Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature 452(7187), 654–658 (2008). https://doi.org/10.1038/nature06663
  23. J. Hou, Q. Chen, X. Wu, D. Zhao, H. Reuveni et al., S1PR3 signaling drives bacterial killing and is required for survival in bacterial sepsis. Am. J. Resp. Crit Care 196(12), 1559–1570 (2017). https://doi.org/10.1164/rccm.201701-0241OC
  24. A. Bouchon, F. Facchetti, M.A. Weigand, M. Colonna, Trem-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410(6832), 1103–1107 (2001). https://doi.org/10.1038/35074114
  25. Q. Chen, K. Zhang, Y. Jin, T. Zhu, B. Cheng et al., Triggering receptor expressed on myeloid cells-2 protects against polymicrobial sepsis by enhancing bacterial clearance. Am. J. Resp. Crit. Care 188(2), 201–212 (2013). https://doi.org/10.1164/rccm.201211-1967OC
  26. Q. Chen, Y. Jin, K. Zhang, H. Li, W. Chen et al., Alarmin HNP-1 promotes pyroptosis and IL-1beta release through different roles of NLRP3 inflammasome via P2X7 in LPS-primed macrophages. Innate Immun. 20(3), 290–300 (2014). https://doi.org/10.1177/1753425913490575
  27. Q. Chen, Y. Yang, J. Hou, Q. Shu, Y. Yin et al., Increased gene copy number of defa1/defa3 worsens sepsis by inducing endothelial pyroptosis. Proc. Natl. Acad. Sci. USA 116(8), 3161–3170 (2019). https://doi.org/10.1073/pnas.1812947116
  28. N. Arulkumaran, M.L. Sixma, S. Pollen, E. Ceravola, E. Jentho et al., P2X7 receptor antagonism ameliorates renal dysfunction in a rat model of sepsis. Phys. Rep. 6(5), e13622 (2018). https://doi.org/10.14814/phy2.13622
  29. X.W. Qian, T. Numata, K. Zhang, C.X. Li, J.C. Hou et al., Transient receptor potential melastatin 2 protects mice against polymicrobial sepsis by enhancing bacterial clearance. Anesthesiology 121(2), 336–351 (2014). https://doi.org/10.1097/ALN.0000000000000275
  30. Z. Zhang, P. Cui, K. Zhang, Q. Chen, X. Fang, Transient receptor potential melastatin 2 regulates phagosome maturation and is required for bacterial clearance in escherichia coli sepsis. Anesthesiology 126(1), 128–139 (2017). https://doi.org/10.1097/ALN.0000000000001430
  31. L. Wang, T.-M. Fu, Y. Zhou, S. Xia, A. Greka et al., Structures and gating mechanism of human TRPM2. Science 362(eaav6421), 4809 (2018). https://doi.org/10.1126/science.aav4809
  32. H.R. Schmidt, S. Zheng, E. Gurpinar, A. Koehl, A. Manglik et al., Crystal structure of the human sigma1 receptor. Nature 532(7600), 527–530 (2016). https://doi.org/10.1038/nature17391
  33. D.A. Rosen, S.M. Seki, A. Fernández-Castañeda, R.M. Beiter, J.D. Eccles et al., Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci. Transl. Med. 11, eaau5266 (2019). https://doi.org/10.1126/scitranslmed.aau5266
  34. A. Rhodes, L.E. Evans, W. Alhazzani, M.M. Levy, M. Antonelli et al., Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intens. Care Med. 43(3), 304–377 (2017). https://doi.org/10.1007/s00134-017-4683-6
  35. C.W. Seymour, F. Gesten, H.C. Prescott, M.E. Friedrich, T.J. Iwashyna et al., Time to treatment and mortality during mandated emergency care for sepsis. N. Engl. J. Med. 376(23), 2235–2244 (2017). https://doi.org/10.1056/NEJMoa1703058
  36. B.-T. Huynh, M. Padget, B. Garin, E. Delarocque-Astagneau, D. Guillemot, Bacterial neonatal sepsis and antibiotic resistance in low-income countries. Lancet 387(10018), 533–534 (2016). https://doi.org/10.1016/s0140-6736(16)00220-8
  37. K.E. Drexler, Molecular engineering: an approach to the development of general capabilities for molecular manipulation. Proc. Natl. Acad. Sci. USA 78(9), 5275–5278 (1981). https://doi.org/10.1073/pnas.78.9.5275
  38. R.T. Sadikot, The potential role of nano- and micro-technology in the management of critical illnesses. Adv. Drug Deliver. Rev. 77(1), 27–31 (2014). https://doi.org/10.1016/j.addr.2014.07.004
  39. J. Shi, P.W. Kantoff, R. Wooster, O.C. Farokhzad, Cancer nanomedicine: Progress, challenges and opportunities. Nat. Rev. Cancer 17(1), 20–37 (2017). https://doi.org/10.1038/nrc.2016.108
  40. W. Jiang, H. Yuan, C.K. Chan, C.A. von Roemeling, Z. Yan et al., Lessons from immuno-oncology: a new era for cancer nanomedicine? Nat. Rev. Drug Discov. 16(6), 369–370 (2017). https://doi.org/10.1038/nrd.2017.34
  41. M.E. Lobatto, V. Fuster, Z.A. Fayad, W.J. Mulder, Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat. Rev. Drug Discov. 10(11), 835–852 (2011). https://doi.org/10.1038/nrd3578
  42. O. Veiseh, B.C. Tang, K.A. Whitehead, D.G. Anderson, R. Langer, Managing diabetes with nanomedicine: challenges and opportunities. Nat. Rev. Drug Discov. 14(1), 45–57 (2015). https://doi.org/10.1038/nrd4477
  43. A.D. Smith, Big moment for nanotech: oncology therapeutics poised for a leap (2013)
  44. G. Luo, Q. Yang, B. Yao, Y. Tian, R. Hou et al., SLP-coated liposomes for drug delivery and biomedical applications: potential and challenges. Int. J. Nanomed. 14(1), 1359–1383 (2019). https://doi.org/10.2147/IJN.S189935
  45. W. Wang, A. Shao, S. Feng, M. Ding, G. Luo, Physicochemical characterization and gastrointestinal adhesion of s-layer proteins-coating liposomes. Int. J. Pharmaceut. 529(1–2), 227–237 (2017). https://doi.org/10.1016/j.ijpharm.2017.07.006
  46. A. Bernkop-Schnurch, A. Jalil, Do drug release studies from sedds make any sense? J. Control. Release 271(1), 55–59 (2018). https://doi.org/10.1016/j.jconrel.2017.12.027
  47. C. Kinnear, T.L. Moore, L. Rodriguez-Lorenzo, B. Rothen-Rutishauser, A. Petri-Fink, Form follows function: nanoparticle shape and its implications for nanomedicine. Chem. Rev. 117(17), 11476–11521 (2017). https://doi.org/10.1021/acs.chemrev.7b00194
  48. H. Wang, H. Xie, J. Wang, J. Wu, X. Ma et al., Self-assembling prodrugs by precise programming of molecular structures that contribute distinct stability, pharmacokinetics, and antitumor efficacy. Adv. Funct. Mater. 25(31), 4956–4965 (2015). https://doi.org/10.1002/adfm.201501953
  49. J. Wan, Y. Qiao, X. Chen, J. Wu, L. Zhou et al., Structure-guided engineering of cytotoxic cabazitaxel for an adaptive nanoparticle formulation: Enhancing the drug safety and therapeutic efficacy. Adv. Funct. Mater. 28(52), 1804229 (2018). https://doi.org/10.1002/adfm.201804229
  50. S.A. Anuj, H.P. Gajera, D.G. Hirpara, B.A. Golakiya, Bactericidal assessment of nano-silver on emerging and re-emerging human pathogens. J. Trace Elem. Med. Biol. 51, 219–225 (2019). https://doi.org/10.1016/j.jtemb.2018.04.028
  51. Y. Li, Y. Chang, X. Lian, L. Zhou, Z. Yu et al., Silver nanoparticles for enhanced cancer theranostics: in vitro and in vivo perspectives. J. Biomed. Nanotechnol. 14(9), 1515–1542 (2018). https://doi.org/10.1166/jbn.2018.2614
  52. J.R. Melamed, R.S. Riley, D.M. Valcourt, E.S. Day, Using gold nanoparticles to disrupt the tumor microenvironment: an emerging therapeutic strategy. ACS Nano 10(12), 10631–10635 (2016). https://doi.org/10.1021/acsnano.6b07673
  53. W. Gao, Y. Xiong, Q. Li, H. Yang, Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics. Front. Physiol. 8(1), 508 (2017). https://doi.org/10.3389/fphys.2017.00508
  54. P. Cui, X. Fang, Pathogenesis of infection in surgical patients. Curr. Opin. Crit. Care 21(4), 343–350 (2015). https://doi.org/10.1097/MCC.0000000000000227
  55. R. Lei, J. Hou, Q. Chen, W. Yuan, B. Cheng et al., Self-assembling myristoylated human alpha-defensin 5 as a next-generation nanobiotics potentiates therapeutic efficacy in bacterial infection. ACS Nano 12, 5284–5296 (2018). https://doi.org/10.1021/acsnano.7b09109
  56. A. Balakrishnan, P. DasSarma, O. Bhattacharjee, J.M. Kim, S. DasSarma et al., Halobacterial nano vesicles displaying murine bactericidal permeability-increasing protein rescue mice from lethal endotoxic shock. Sci. Rep. 6, 33679 (2016). https://doi.org/10.1038/srep33679
  57. F.H. Liao, T.H. Wu, Y.T. Huang, W.J. Lin, C.J. Su et al., Subnanometer gold clusters adhere to lipid a for protection against endotoxin-induced sepsis. Nano Lett. 18(5), 2864–2869 (2018). https://doi.org/10.1021/acs.nanolett.7b05464
  58. J.L. Perry, K.P. Herlihy, M. Napier, J.M. Desimon, Print: a novel platform toward shape and size specific nanoparticle theranostics. Acc. Chem. Res. 44(10), 990–998 (2011). https://doi.org/10.1021/ar2000315
  59. S. Mura, P. Couvreur, Nanotheranostics for personalized medicine. Adv. Drug Deliver. Rev. 64(13), 1394–1416 (2012). https://doi.org/10.1016/j.addr.2012.06.006
  60. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit et al., Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751–760 (2007). https://doi.org/10.1038/nnano.2007.387
  61. B.R. Smith, S.S. Gambhir, Nanomaterials for in vivo imaging. Chem. Rev. 117(3), 901–986 (2017). https://doi.org/10.1021/acs.chemrev.6b00073
  62. F.M. Kievit, M. Zhang, Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv. Mater. 23(36), H217-247 (2011). https://doi.org/10.1002/adma.201102313
  63. W.L. Tang, W.H. Tang, S.D. Li, Cancer theranostic applications of lipid-based nanoparticles. Drug Discov. Today 23(5), 1159–1166 (2018). https://doi.org/10.1016/j.drudis.2018.04.007
  64. Y. Liu, P. Bhattarai, Z. Dai, X. Chen, Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. Chem. Soc. Rev. 48(7), 2053–2108 (2019). https://doi.org/10.1039/c8cs00618k
  65. S. Mohamed, S. Veeranarayanan, T. Maekawa, S. Kumar, External stimulus responsive inorganic nanomaterials for cancer theranostics. Adv. Drug Deliver. Rev. 138(1), 18–40 (2019). https://doi.org/10.1016/j.addr.2018.10.007
  66. P. Jagtap, V. Sritharan, S. Gupta, Nanotheranostic approaches for management of bloodstream bacterial infections. Nanomed-Nanotechnol. 13(1), 329–341 (2017). https://doi.org/10.1016/j.nano.2016.09.005
  67. M.D. Howard, E.D. Hood, B. Zern, V.V. Shuvaev, T. Grosser et al., Nanocarriers for vascular delivery of anti-inflammatory agents. Annu. Rev. Pharmacol. 54(1), 205–226 (2014). https://doi.org/10.1146/annurev-pharmtox-011613-140002
  68. A. Kumar, R.K. Chaudhary, R. Singh, S.P. Singh, S.Y. Wang et al., Nanotheranostic applications for detection and targeting neurodegenerative diseases. Front. Neurosci. 14(1), 305 (2020). https://doi.org/10.3389/fnins.2020.00305
  69. F. Liu, L. Lin, Y. Zhang, Y. Wang, S. Sheng et al., A tumor-microenvironment-activated nanozyme-mediated theranostic nanoreactor for imaging-guided combined tumor therapy. Adv. Mater. 31(40), e1902885 (2019). https://doi.org/10.1002/adma.201902885
  70. C.F. Markwalter, A.G. Kantor, C.P. Moore, K.A. Richardson, D.W. Wright, Inorganic complexes and metal-based nanomaterials for infectious disease diagnostics. Chem. Rev. 119(2), 1456–1518 (2019). https://doi.org/10.1021/acs.chemrev.8b00136
  71. B. Yang, Y. Chen, J. Shi, Reactive oxygen species (ROS)-based nanomedicine. Chem. Rev. 119(8), 4881–4985 (2019). https://doi.org/10.1021/acs.chemrev.8b00626
  72. R. Eivazzadeh-Keihan, E. Bahojb-Noruzi, K. Khanmohammadi-Chenab, A. Jafari, F. Radinekiyan et al., Metal-based nanoparticles for bone tissue engineering. J. Tissue Eng. Regen. Med. 14, 1687–1714 (2020). https://doi.org/10.1002/term.3131
  73. G. Yang, S.Z.F. Phua, A.K. Bindra, Y. Zhao, Degradability and clearance of inorganic nanoparticles for biomedical applications. Adv. Mater. 31(10), e1805730 (2019). https://doi.org/10.1002/adma.201805730
  74. H.P. Lee, A.K. Gaharwar, Light-responsive inorganic biomaterials for biomedical applications. Adv. Sci. 7(17), 2000863 (2020). https://doi.org/10.1002/advs.202000863
  75. J.H. Lee, H.Y. Cho, H.K. Choi, J.Y. Lee, J.W. Choi, Application of gold nanoparticle to plasmonic biosensors. Int. J. Mol. Sci. 19(7), 2021 (2018). https://doi.org/10.3390/ijms19072021
  76. N. Wang, H. Dai, L. Sai, H. Ma, M. Lin, Copper ion-assisted gold nanoparticle aggregates for electrochemical signal amplification of lipopolysaccharide sensing. Biosens. Bioelectron. 126, 529–534 (2019). https://doi.org/10.1016/j.bios.2018.11.021
  77. J.H. Kim, J.S. Suh, J. Yang, Labeling-free detection of ECD-HER2 protein using aptamer-based nano-plasmonic sensor. Nanotechnology 31(17), 175501 (2020). https://doi.org/10.1088/1361-6528/ab68fa
  78. V.A. Tran, V.G. Vo, K. Shim, S.W. Lee, S.S.A. An, Multimodal mesoporous silica nanocarriers for dual stimuli-responsive drug release and excellent photothermal ablation of cancer cells. Int. J. Nanomed. 15(1), 7667–7685 (2020). https://doi.org/10.2147/IJN.S254344
  79. Y. Zhang, C. Guo, L. Liu, J. Xu, H. Jiang et al., Zno-based multifunctional nanocomposites to inhibit progression and metastasis of melanoma by eliciting antitumor immunity via immunogenic cell death. Theranostics 10(24), 11197–11214 (2020). https://doi.org/10.7150/thno.44920
  80. D. Jiang, D. Ni, Z.T. Rosenkrans, P. Huang, X. Yan et al., Nanozyme: New horizons for responsive biomedical applications. Chem. Soc. Rev. 48(14), 3683–3704 (2019). https://doi.org/10.1039/c8cs00718g
  81. S. Gao, H. Lin, H. Zhang, H. Yao, Y. Chen et al., Nanocatalytic tumor therapy by biomimetic dual inorganic nanozyme-catalyzed cascade reaction. Adv. Sci. 6(3), 1801733 (2019). https://doi.org/10.1002/advs.201801733
  82. X. Hu, F. Li, F. Xia, X. Guo, N. Wang et al., Biodegradation-mediated enzymatic activity-tunable molybdenum oxide nanourchins for tumor-specific cascade catalytic therapy. J. Am. Chem. Soc. 142(3), 1636–1644 (2020). https://doi.org/10.1021/jacs.9b13586
  83. Y.F. Liu, Y. Cheng, H. Zhang, M. Zhou, Y.J. Yu et al., Integrated cascade nanozyme catalyzes in vivo ROS scavenging for anti-inflammatory therapy. Sci. Adv. 6(1), 2695 (2020). https://doi.org/10.1126/sciadv.abb2695
  84. N. Kamaly, B. Yameen, J. Wu, O.C. Farokhzad, Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem. Rev. 116(4), 2602–2663 (2016). https://doi.org/10.1021/acs.chemrev.5b00346
  85. K. Ulbrich, K. Hola, V. Subr, A. Bakandritsos, J. Tucek et al., Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies. Chem. Rev. 116(9), 5338–5431 (2016). https://doi.org/10.1021/acs.chemrev.5b00589
  86. I. Ekladious, Y.L. Colson, M.W. Grinstaff, Polymer-drug conjugate therapeutics: Advances, insights and prospects. Nat. Rev. Drug Discov. 18(4), 273–294 (2019). https://doi.org/10.1038/s41573-018-0005-0
  87. S. Rashki, K. Asgarpour, H. Tarrahimofrad, M. Hashemipour, M.S. Ebrahimi et al., Chitosan-based nanoparticles against bacterial infections. Carbohyd. Polym. 251(1), 117108 (2021). https://doi.org/10.1016/j.carbpol.2020.117108
  88. M. Lara-Velazquez, R. Alkharboosh, E.S. Norton, C. Ramirez-Loera, W.D. Freeman et al., Chitosan-based non-viral gene and drug delivery systems for brain cancer. Front. Neurol. 11(1), 740 (2020). https://doi.org/10.3389/fneur.2020.00740
  89. X. Lang, T. Wang, M. Sun, X. Chen, Y. Liu, Advances and applications of chitosan-based nanomaterials as oral delivery carriers: a review. Int. J. Biol. Macromol. 154(1), 433–445 (2020). https://doi.org/10.1016/j.ijbiomac.2020.03.148
  90. P. Severino, C.F. da Silva, L.N. Andrade, D. de Lima-Oliveira, J. Campos et al., Alginate nanoparticles for drug delivery and targeting. Curr. Pharm. Des. 25(11), 1312–1334 (2019). https://doi.org/10.2174/1381612825666190425163424
  91. J. Ding, Y. Yao, J. Li, Y. Duan, J.R. Nakkala et al., A reactive oxygen species scavenging and O2 generating injectable hydrogel for myocardial infarction treatment in vivo. Small 16, 2005038 (2020). https://doi.org/10.1002/smll.202005038
  92. Y. Hong, F. Zhou, Y. Hua, X. Zhang, C. Ni et al., A strongly adhesive hemostatic hydrogel for the repair of arterial and heart bleeds. Nat. Commun. 10(1), 2060 (2019). https://doi.org/10.1038/s41467-019-10004-7
  93. Y.W. Chen, W.L. Shen, C.Q. Tang, J.Y. Huang, C.M. Fan et al., Targeted pathological collagen delivery of sustained-release rapamycin to prevent heterotopic ossification. Sci. Adv. 6(1), 9526 (2019). https://doi.org/10.1126/sciadv.aay9526
  94. J. Di, F. Xie, Y. Xu, When liposomes met antibodies: drug delivery and beyond. Adv. Drug Deliver. Rev. (2020). https://doi.org/10.1016/j.addr.2020.09.003
  95. J.J. Sonju, A. Dahal, S.S. Singh, S.D. Jois, Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment. J. Control. Release (2020). https://doi.org/10.1016/j.jconrel.2020.09.055
  96. A. Al-Saqr, M.F. Aldawsari, H. Alrbyawi, I. Poudel, M. Annaji et al., Co-delivery of hispolon and doxorubicin liposomes improves efficacy against melanoma cells. AAPS PharmSciTech 21(8), 304 (2020). https://doi.org/10.1208/s12249-020-01846-2
  97. Q. Wang, P. Tardi, N. Sadowski, S. Xie, D. Heller et al., Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals. Nanomed. Nanotechnol. 30(1), 102275 (2020). https://doi.org/10.1016/j.nano.2020.102275
  98. L. Shi, Y. Wang, Q. Wang, Z. Jiang, L. Ren et al., Transforming a toxic drug into an efficacious nanomedicine using a lipoprodrug strategy for the treatment of patient-derived melanoma xenografts. J. Control. Release 324(1), 289–302 (2020). https://doi.org/10.1016/j.jconrel.2020.05.025
  99. Y. Tang, X. Wang, J. Li, Y. Nie, G. Liao et al., Overcoming the reticuloendothelial system barrier to drug delivery with a “don’t-eat-us” strategy. ACS Nano 13(11), 13015–13026 (2019). https://doi.org/10.1021/acsnano.9b05679
  100. Z. Zhang, J. Guan, Z. Jiang, Y. Yang, J. Liu et al., Brain-targeted drug delivery by manipulating protein corona functions. Nat. Commun. 10(1), 3561 (2019). https://doi.org/10.1038/s41467-019-11593-z
  101. H. Wang, X. Xu, X. Guan, S. Shen, X. Huang et al., Liposomal 9-aminoacridine for treatment of ischemic stroke: from drug discovery to drug delivery. Nano Lett. 20(3), 1542–1551 (2020). https://doi.org/10.1021/acs.nanolett.9b04018
  102. J. Zhou, A.V. Kroll, M. Holay, R.H. Fang, L. Zhang, Biomimetic nanotechnology toward personalized vaccines. Adv. Mater. 32(13), e1901255 (2020). https://doi.org/10.1002/adma.201901255
  103. Z. Chen, Z. Wang, Z. Gu, Bioinspired and biomimetic nanomedicines. Acc. Chem. Res. 52(5), 1255–1264 (2019). https://doi.org/10.1021/acs.accounts.9b00079
  104. R.H. Fang, A.V. Kroll, W. Gao, L. Zhang, Cell membrane coating nanotechnology. Adv. Mater. 30(23), e1706759 (2018). https://doi.org/10.1002/adma.201706759
  105. J.C. Harris, M.A. Scully, E.S. Day, Cancer cell membrane-coated nanoparticles for cancer management. Cancers 11(12), 1836 (2019). https://doi.org/10.3390/cancers11121836
  106. V. Cagno, P. Andreozzi, M. D’Alicarnasso, P. Jacob-Silva, M. Mueller et al., Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. Nat. Mater. 17(2), 195–203 (2018). https://doi.org/10.1038/nmat5053
  107. J. Wang, P. Li, Y. Yu, Y. Fu, H. Jiang et al., Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity. Science 367(6480), 0810 (2020). https://doi.org/10.1126/science.aau0810
  108. Y. Liu, J. Luo, X. Chen, W. Liu, T. Chen, Cell membrane coating technology: a promising strategy for biomedical applications. Nano-Micro Lett. 11(1), 100 (2019). https://doi.org/10.1007/s40820-019-0330-9
  109. R. Molinaro, C. Corbo, J.O. Martinez, F. Taraballi, M. Evangelopoulos et al., Biomimetic proteolipid vesicles for targeting inflamed tissues. Nat. Mater. 15(9), 1037–1046 (2016). https://doi.org/10.1038/nmat4644
  110. J. Koo, T. Escajadillo, L. Zhang, V. Nizet, S.M. Lawrence, Erythrocyte-coated nanoparticles block cytotoxic effects of group b streptococcus beta-hemolysin/cytolysin. Front. Pediatr. 7(1), 410 (2019). https://doi.org/10.3389/fped.2019.00410
  111. Y. Lu, Q. Hu, C. Jiang, Z. Gu, Platelet for drug delivery. Curr. Opin. Biotechnol. 58(1), 81–91 (2019). https://doi.org/10.1016/j.copbio.2018.11.010
  112. J. Zhuang, H. Gong, J.R. Zhou, Q.Z. Zhang, W.W. Gao et al., Targeted gene silencing in vivo by platelet membrane-coated metal-organic framework nanoparticles. Sci. Adv. 6(1), 6108 (2020). https://doi.org/10.1126/sciadv.aaz6108
  113. G. Zhang, G.R. Campbell, Q.Z. Zhang, E. Maule, J. Hanna et al., Cd4+ t cell-mimicking nanoparticles broadly neutralize HIV-1 and suppress viral replication through autophagy. mBio 11(5), 00903–00920 (2020). https://doi.org/10.1128/mBio.00903-20
  114. C. Tapeinos, F. Tomatis, M. Battaglini, A. Larranaga, A. Marino et al., Cell membrane-coated magnetic nanocubes with a homotypic targeting ability increase intracellular temperature due to ros scavenging and act as a versatile theranostic system for glioblastoma multiforme. Adv. Health Mater. 8(18), e1900612 (2019). https://doi.org/10.1002/adhm.201900612
  115. Y. Jiang, N. Krishnan, J. Zhou, S. Chekuri, X. Wei et al., Engineered cell-membrane-coated nanoparticles directly present tumor antigens to promote anticancer immunity. Adv. Mater. 32(30), e2001808 (2020). https://doi.org/10.1002/adma.202001808
  116. Y. Zhang, Y. Chen, C. Lo, J. Zhuang, P. Angsantikul et al., Inhibition of pathogen adhesion by bacterial outer membrane-coated nanoparticles. Angew. Chem. Int. Ed. 58(33), 11404–11408 (2019). https://doi.org/10.1002/anie.201906280
  117. Q. Zhang, A. Honko, J. Zhou, H. Gong, S.N. Downs et al., Cellular nanosponges inhibit SARS-CoV-2 infectivity. Nano Lett. 20(7), 5570–5574 (2020). https://doi.org/10.1021/acs.nanolett.0c02278
  118. F. Gorjikhah, S. Davaran, R. Salehi, M. Bakhtiari, A. Hasanzadeh et al., Improving “lab-on-a-chip” techniques using biomedical nanotechnology: a review. Artif. Cell. Nanomed. Biotechnol. 44(7), 1609–1614 (2016). https://doi.org/10.3109/21691401.2015.1129619
  119. B. Hu, C. Owh, P.L. Chee, W.R. Leow, X. Liu et al., Supramolecular hydrogels for antimicrobial therapy. Chem. Soc. Rev. 47(18), 6917–6929 (2018). https://doi.org/10.1039/c8cs00128f
  120. S. Wang, Y. Gao, Q. Jin, J. Ji, Emerging antibacterial nanomedicine for enhanced antibiotic therapy. Biomater. Sci. 8, 6825–6839 (2020). https://doi.org/10.1039/d0bm00974a
  121. D.G. Remick, Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Curr. Pharm. Des. 9(1), 75–82 (2003). https://doi.org/10.2174/1381612033392567
  122. M.D.V. Marco-Ranieri, M.D.B. Taylor-Thompson, M.D. Philip, S. Barie, M.D. Jean-François-Dhainaut et al., Drotrecogin alfa (activated) in adults with septic shock. N. Engl. J. Med. 366(22), 2055–2064 (2012). https://doi.org/10.1056/NEJMoa1202290
  123. J. Lou-Franco, B. Das, C. Elliott, C. Cao, Gold nanozymes: from concept to biomedical applications. Nano-Micro Lett. 13(1), 10 (2020). https://doi.org/10.1007/s40820-020-00532-z
  124. N. Feliu, D. Docter, M. Heine, P. Del Pino, S. Ashraf et al., In vivo degeneration and the fate of inorganic nanoparticles. Chem. Soc. Rev. 45(9), 2440–2457 (2016). https://doi.org/10.1039/c5cs00699f
  125. N.D. Donahue, H. Acar, S. Wilhelm, Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Adv. Drug Deliver. Rev. 143(1), 68–96 (2019). https://doi.org/10.1016/j.addr.2019.04.008
  126. S. Ravindran, J.K. Suthar, R. Rokade, P. Deshpande, P. Singh et al., Pharmacokinetics, metabolism, distribution and permeability of nanomedicine. Curr. Drug Metab. 19(4), 327–334 (2018). https://doi.org/10.2174/1389200219666180305154119
  127. S.E. McNeil, Nanoparticle therapeutics a personal perspective. Wires Nanomed. Nanobi. 1(1), 264–271 (2009). https://doi.org/10.1002/wnan.006
  128. S. Ranjbar-Bahadori, A. Mulgaonkar, R. Hart, C.Y. Wu, D. Zhang et al., Radiolabeling strategies and pharmacokinetic studies for metal based nanotheranostics. Wires Nanomed. Nanobi. (2020). https://doi.org/10.1002/wnan.1671
  129. H. Arami, A. Khandhar, D. Liggitt, K.M. Krishnan, In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem. Soc. Rev. 44(23), 8576–8607 (2015). https://doi.org/10.1039/c5cs00541h
  130. J. Lu, J. Wang, D. Ling, Surface engineering of nanoparticles for targeted delivery to hepatocellular carcinoma. Small 14(5), 1702037 (2018). https://doi.org/10.1002/smll.201702037
  131. E. Ben-Akiva, R.A. Meyer, H.Z. Yu, J.T. Smith, D.M. Pardoll et al., Biomimetic anisotropic polymeric nanoparticles coated with red blood cell membranes for enhanced circulation and toxin removal. Sci. Adv. 6(1), 9035 (2020). https://doi.org/10.1126/sciadv.aay9035
  132. F. Bloos, K. Reinhart, Rapid diagnosis of sepsis. Virulence 5(1), 154–160 (2014). https://doi.org/10.4161/viru.27393
  133. X.Z. Mou, X.Y. Chen, J. Wang, Z. Zhang, Y. Yang et al., Bacteria-instructed click chemistry between functionalized gold nanoparticles for point-of-care microbial detection. ACS Appl. Mater. Interfaces 11(26), 23093–23101 (2019). https://doi.org/10.1021/acsami.9b09279
  134. M. Sun, A. Qu, C. Hao, X. Wu, L. Xu et al., Chiral upconversion heterodimers for quantitative analysis and bioimaging of antibiotic-resistant bacteria in vivo. Adv. Mater. 30(50), e1804241 (2018). https://doi.org/10.1002/adma.201804241
  135. I.K. Herrmann, S. Bertazzo, D.J.P. O’Callaghan, A.A. Schlegel et al., Differentiating sepsis from non-infectious systemic inflammation based on microvesicle-bacteria aggregation. Nanoscale 7(32), 13511–13520 (2015). https://doi.org/10.1039/c5nr01851j
  136. L. Wang, W.J. Zhao, M.B. O’Donoghue, W. Tan, Fluorescent nanoparticles for multiplexed bacteria monitoring. Bioconjugate Chem. 18(2), 297–301 (2007). https://doi.org/10.1021/bc060255n
  137. G. Santopolo, A. Doménech-Sánchez, S.M. Russell, R. de la Rica, Ultrafast and ultrasensitive naked-eye detection of urease-positive bacteria with plasmonic nanosensors. ACS Sensors 4(4), 961–967 (2019). https://doi.org/10.1021/acssensors.9b00063
  138. C.-W. Lee, H.-Y. Chang, J.-K. Wu, F.-G. Tseng, Ultra-sensitive electrochemical detection of bacteremia enabled by redox-active gold nanoparticles (raGNPs) in a nano-sieving microfluidic system (NS-MFS). Biosens. Bioelectron. 133(1), 215–222 (2019). https://doi.org/10.1016/j.bios.2019.03.040
  139. J. Gao, L. Li, P.L. Ho, G.C. Mak, H. Gu et al., Combining fluorescent probes and biofunctional magnetic nanoparticles for rapid detection of bacteria in human blood. Adv. Mater. 18(23), 3145–3148 (2006). https://doi.org/10.1002/adma.200601058
  140. A. Belushkin, F. Yesilkoy, H. Altug, Nanoparticle-enhanced plasmonic biosensor for digital biomarker detection in a microarray. ACS Nano 12(5), 4453–4461 (2018). https://doi.org/10.1021/acsnano.8b00519
  141. D.K. Changlin-Fu, Pilot application of magnetic nanoparticle-based biosensor for necrotizing enterocolitis. J. Proteomics. Bioinf. 5(1), 002 (2015). https://doi.org/10.4172/jpb.S5-002
  142. R.K. Gupta, A. Periyakaruppan, M. Meyyappan, J.E. Koehne, Label-free detection of c-reactive protein using a carbon nanofiber based biosensor. Biosens. Bioelectron. 59(1), 112–119 (2014). https://doi.org/10.1016/j.bios.2014.03.027
  143. L. Cao, J. Kiely, M. Piano, R. Luxton, A copper oxide/zinc oxide composite nano-surface for use in a biosensor. Materials 12(7), 1126 (2019). https://doi.org/10.3390/ma12071126
  144. L. Zhang, S. Tong, J. Zhou, G. Bao, Accurate quantification of disease markers in human serum using iron oxide nanoparticle-linked immunosorbent assay. Theranostics 6(9), 1353–1361 (2016). https://doi.org/10.7150/thno.16093
  145. L. Cao, J. Kiely, M. Piano, R. Luxton, Facile and inexpensive fabrication of zinc oxide based bio-surfaces for c-reactive protein detection. Sci. Rep. 8(1), 12687 (2018). https://doi.org/10.1038/s41598-018-30793-z
  146. K.M. Park, D.J. Chung, M. Choi, T. Kang, J. Jeong, Fluorescent fullerene nanoparticle-based lateral flow immunochromatographic assay for rapid quantitative detection of c-reactive protein. Nano Converg. 6(1), 35 (2019). https://doi.org/10.1186/s40580-019-0207-0
  147. I. Letchumanan, M.K. Md-Arshad, S.R. Balakrishnan, S.C.B. Gopinath, Gold-nanorod enhances dielectric voltammetry detection of c-reactive protein: a predictive strategy for cardiac failure. Biosens. Bioelectron. 130(1), 40–47 (2019). https://doi.org/10.1016/j.bios.2019.01.042
  148. A. Prajapati, N. Verma, A. Pandya, Highly sensitive vertical flow based point-of-care immunokit for rapid and early detection of human CRP as a cardiovascular risk factor. Biomed. Microdevices 22(2), 28 (2020). https://doi.org/10.1007/s10544-020-00480-w
  149. A. Liu, X. Wang, Amperometric immunosensor of procalcitonin based on amplification strategy of ferrocene-modified gold nanoparticles. Int. J. Electrochem. Sci. 10(1), 9342–9350 (2015)
  150. P. Li, W. Zhang, X. Zhou, L. Zhang, C60 carboxyfullerene-based functionalised nanohybrids as signal-amplifying tags for the ultrasensitive electrochemical detection of procalcitonin. Clin. Biochem. 48(3), 156–161 (2015). https://doi.org/10.1016/j.clinbiochem.2014.09.017
  151. Z.H. Yang, S. Ren, Y. Zhuo, R. Yuan, Y.Q. Chai, Cu/Mn double-doped CeO2 nanocomposites as signal tags and signal amplifiers for sensitive electrochemical detection of procalcitonin. Anal. Chem. 89(24), 13349–13356 (2017). https://doi.org/10.1021/acs.analchem.7b03502
  152. C.Y. Chiang, T.T. Huang, C.H. Wang, C.J. Huang, T.H. Tsai et al., Fiber optic nanogold-linked immunosorbent assay for rapid detection of procalcitonin at femtomolar concentration level. Biosens. Bioelectron. 151(1), 111871 (2020). https://doi.org/10.1016/j.bios.2019.111871
  153. F. Liu, G. Xiang, R. Yuan, X. Chen, F. Luo et al., Procalcitonin sensitive detection based on graphene-gold nanocomposite film sensor platform and single-walled carbon nanohorns/hollow pt chains complex as signal tags. Biosens. Bioelectron. 60(1), 210–217 (2014). https://doi.org/10.1016/j.bios.2014.03.071
  154. W. Jing, Y. Wang, Y. Yang, Y. Wang, G. Ma et al., Time-resolved digital immunoassay for rapid and sensitive quantitation of procalcitonin with plasmonic imaging. ACS Nano 13(8), 8609–8617 (2019). https://doi.org/10.1021/acsnano.9b02771
  155. X. Xu, X. Song, R. Nie, Y. Yang, Y. Chen et al., Ultra-sensitive capillary immunosensor combining porous-layer surface modification and biotin-streptavidin nano-complex signal amplification: application for sensing of procalcitonin in serum. Talanta 205(1), 120089 (2019). https://doi.org/10.1016/j.talanta.2019.06.089
  156. Q. Lin, J. Wu, X. Fang, J. Kong, Washing-free centrifugal microchip fluorescence immunoassay for rapid and point-of-care detection of protein. Anal. Chim. Acta 1118(1), 18–25 (2020). https://doi.org/10.1016/j.aca.2020.04.031
  157. W.W. Xiong, G.H. Yang, X.C. Wu, J.J. Zhu, Aqueous synthesis of color-tunable CuInS2/ZnS nanocrystals for the detection of human interleukin 6. ACS Appl. Mater. Interfaces 5(16), 8210–8216 (2013). https://doi.org/10.1021/am402328t
  158. Z. Hao, Y. Pan, W. Shao, Q. Lin, X. Zhao, Graphene-based fully integrated portable nanosensing system for on-line detection of cytokine biomarkers in saliva. Biosens. Bioelectron. 134(1), 16–23 (2019). https://doi.org/10.1016/j.bios.2019.03.053
  159. U.Y. Lau, S.S. Saxer, J. Lee, E. Bat, H.D. Maynard, Direct write protein patterns for multiplexed cytokine detection from live cells using electron beam lithography. ACS Nano 10(1), 723–729 (2016). https://doi.org/10.1021/acsnano.5b05781
  160. E. Sánchez-Tirado, C. Salvo, A. González-Cortés, P. Yáñez-Sedeño, F. Langa et al., Electrochemical immunosensor for simultaneous determination of interleukin-1 beta and tumor necrosis factor alpha in serum and saliva using dual screen printed electrodes modified with functionalized double–walled carbon nanotubes. Anal. Chim. Acta 959(1), 66–73 (2017). https://doi.org/10.1016/j.aca.2016.12.034
  161. B.R. Oh, N.T. Huang, W.Q. Chen, J. Hwan-Seo, P.Y. Chen et al., Integrated nanoplasmonic sensing for cellular functional immunoanalysis using human blood. ACS Nano 8(3), 2667–2676 (2014). https://doi.org/10.1021/nn406370u
  162. Y. Park, B. Ryu, B.R. Oh, Y. Song, X. Liang et al., Biotunable nanoplasmonic filter on few-layer MoS2 for rapid and highly sensitive cytokine optoelectronic immunosensing. ACS Nano 11(6), 5697–5705 (2017). https://doi.org/10.1021/acsnano.7b01162
  163. J. Min, M. Nothing, B. Coble, H. Zheng, J. Park et al., Integrated biosensor for rapid and point-of-care sepsis diagnosis. ACS Nano 12(4), 3378–3384 (2018). https://doi.org/10.1021/acsnano.7b08965
  164. P.Y. Chen, M.T. Chung, W. McHugh, R. Nidetz, Y.W. Li et al., Multiplex serum cytokine immunoassay using nanoplasmonic biosensor microarrays. ACS Nano 9(4), 4173–4181 (2015). https://doi.org/10.1021/acsnano.5b00396
  165. M.N. Hsu, S.C. Wei, D.T. Phan, Y. Zhang, C.H. Chen, Nano-in-micro smart hydrogel composite for a rapid sensitive immunoassay. Adv. Healthc. Mater. 8(4), e1801277 (2019). https://doi.org/10.1002/adhm.201801277
  166. H.W. Gu, P.L. Ho, K.W.T. Tsang, L. Wang, B. Xu, Using biofunctional magnetic nanoparticles to capture vancomycin-resistant. J. Am. Chem. Soc. 125, 15702–15703 (2003). https://doi.org/10.1021/ja0359310
  167. R. Frank, R. Hargreaves, Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2(7), 566–580 (2003). https://doi.org/10.1038/nrd1130
  168. C.F. Oliveira, F.A. Botoni, C.R. Oliveira, C.B. Silva, H.A. Pereira et al., Procalcitonin versus c-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Crit. Care Med. 41(10), 2336–2343 (2013). https://doi.org/10.1097/CCM.0b013e31828e969f
  169. M.K. Masud, J. Na, M. Younus, M.S.A. Hossain, Y. Bando et al., Superparamagnetic nanoarchitectures for disease-specific biomarker detection. Chem. Soc. Rev. 48(24), 5717–5751 (2019). https://doi.org/10.1039/c9cs00174c
  170. M. Perfezou, A. Turner, A. Merkoci, Cancer detection using nanoparticle-based sensors. Chem. Soc. Rev. 41(7), 2606–2622 (2012). https://doi.org/10.1039/c1cs15134g
  171. K.K. Jain, Applications of nanobiotechnology in clinical diagnostics. Clin. Chem. 53(11), 2002–2009 (2007). https://doi.org/10.1373/clinchem.2007.090795
  172. N. Widiarti, J.K. Sae, S. Wahyuni, Synthesis CuO–ZnO nanocomposite and its application as an antibacterial agent. IOP Conf. Ser. Mater. Sci. Eng. 172(1), 012036 (2017). https://doi.org/10.1088/1757-899x/172/1/012036
  173. P. Schuetz, C. Bretscher, L. Bernasconi, B. Mueller, Overview of procalcitonin assays and procalcitonin-guided protocols for the management of patients with infections and sepsis. Expert Rev. Mol. Diagn. 17(6), 593–601 (2017). https://doi.org/10.1080/14737159.2017.1324299
  174. C. Wacker, A. Prkno, F.M. Brunkhorst, P. Schlattmann, Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect. Dis. 13(5), 426–435 (2013). https://doi.org/10.1016/s1473-3099(12)70323-7
  175. M. Stocker, W. van Herk, S. el Helou, S. Dutta, M.S. Fontana et al., Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (neopins). Lancet 390(10097), 871–881 (2017). https://doi.org/10.1016/s0140-6736(17)31444-7
  176. M. Meisner, Update on procalcitonin measurements. Ann. Lab. Med. 34(4), 263–273 (2014). https://doi.org/10.3343/alm.2014.34.4.263
  177. E. Mauriz, P. Dey, L.M. Lechuga, Advances in nanoplasmonic biosensors for clinical applications. The Analyst 144(24), 7105–7129 (2019). https://doi.org/10.1039/c9an00701f
  178. C. Nedeva, J. Menassa, H. Puthalakath, Sepsis: inflammation is a necessary evil. Front. Cell Dev. Biol. 7(1), 108 (2019). https://doi.org/10.3389/fcell.2019.00108
  179. D. Rittirsch, M.A. Flierl, P.A. Ward, Harmful molecular mechanisms in sepsis. Nat. Rev. Immunol. 8(10), 776–787 (2008). https://doi.org/10.1038/nri2402
  180. J.D. Spitzberg, A. Zrehen, X.F. van Kooten, A. Meller, Plasmonic-nanopore biosensors for superior single-molecule detection. Adv. Mater. 31(23), e1900422 (2019). https://doi.org/10.1002/adma.201900422
  181. Y.C. Yeh, T.H. Huang, S.C. Yang, C.C. Chen, J.Y. Fang, Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: a review of recent advances. Front. Chem. 8(1), 286 (2020). https://doi.org/10.3389/fchem.2020.00286
  182. M.A. Mohamed, Myco-engineered gold nanoparticles from jahnula aquatica coated with ampicillin/amoxicillin and their antibacterial and anticancer activity against cancer cells. Biotechnol. Lett. 42(1), 151–170 (2020). https://doi.org/10.1007/s10529-019-02764-5
  183. G.B. Hwang, H. Huang, G. Wu, J. Shin, A. Kafizas et al., Photobactericidal activity activated by thiolated gold nanoclusters at low flux levels of white light. Nat. Commun. 11(1), 1207 (2020). https://doi.org/10.1038/s41467-020-15004-6
  184. D.P. Linklater, V.A. Baulin, X. Le Guevel, J.B. Fleury, E. Hanssen et al., Antibacterial action of nanoparticles by lethal stretching of bacterial cell membranes. Adv. Mater. 32, 2005679 (2020). https://doi.org/10.1002/adma.202005679
  185. M.A.M. Jahromi, P.S. Zangabad, S.M.M. Basri, K.S. Zangabad, A. Ghamarypour et al., Nanomedicine and advanced technologies for burns: Preventing infection and facilitating wound healing. Adv. Drug Deliver. Rev. 123(1), 33–64 (2018). https://doi.org/10.1016/j.addr.2017.08.001
  186. J. Verma, J. Kanoujia, P. Parashar, C.B. Tripathi, S.A. Saraf, Wound healing applications of sericin/chitosan-capped silver nanoparticles incorporated hydrogel. Drug Deliv. Transl. Res. 7(1), 77–88 (2017). https://doi.org/10.1007/s13346-016-0322-y
  187. L. Rizzello, P.P. Pompa, Nanosilver-based antibacterial drugs and devices: Mechanisms, methodological drawbacks, and guidelines. Chem. Soc. Rev. 43(5), 1501–1518 (2014). https://doi.org/10.1039/c3cs60218d
  188. X. Li, H. Bai, Y. Yang, J. Yoon, S. Wang et al., Supramolecular antibacterial materials for combatting antibiotic resistance. Adv. Mater. 31(5), e1805092 (2019). https://doi.org/10.1002/adma.201805092
  189. I.R. Scolari, P.L. Paez, M.M. Musri, J.P. Petiti, A. Torres et al., Rifampicin loaded in alginate/chitosan nanoparticles as a promising pulmonary carrier against staphylococcus aureus. Drug Deliv. Transl. Res. 10(5), 1403–1417 (2020). https://doi.org/10.1007/s13346-019-00705-3
  190. D. Mazzaccaro, R. Ticozzi, S. D’Alessandro, S. Delbue, G. Nano et al., Effect of antibiotic-loaded chitosan nanodroplets on enterococci isolated from chronic ulcers of the lower limbs. Future Microbiol. 15(13), 1227–1236 (2020). https://doi.org/10.2217/fmb-2019-0255
  191. C. Hu, F. Zhang, L. Long, Q. Kong, R. Luo et al., Dual-responsive injectable hydrogels encapsulating drug-loaded micelles for on-demand antimicrobial activity and accelerated wound healing. J. Control Release 324(1), 204–217 (2020). https://doi.org/10.1016/j.jconrel.2020.05.010
  192. L.D. Duceac, G. Calin, L. Eva, C. Marcu, E.R. Bogdan-Goroftei et al., Third-generation cephalosporin-loaded chitosan used to limit microorganisms resistance. Materials 13(21), 4792 (2020). https://doi.org/10.3390/ma13214792
  193. Z. Li, G. Luo, W.P. Hu, J.L. Hua, S. Geng et al., Mediated drug release from nanovehicles by black phosphorus quantum dots for efficient therapy of chronic obstructive pulmonary disease. Angew. Chem. Int. Ed. 59(1), 20568–20576 (2020). https://doi.org/10.1002/anie.202008379
  194. E.B. Yahya, F. Jummaat, A.A. Amirul, A.S. Adnan, N.G. Olaiya et al., A review on revolutionary natural biopolymer-based aerogels for antibacterial delivery. Antibiotics 9(10), 648 (2020). https://doi.org/10.3390/antibiotics9100648
  195. X.X. Wu, Y. Zhang, T. Hu, W.X. Li, Z.L. Li et al., Long-term antibacterial composite via alginate aerogel sustained release of antibiotics and Cu used for bone tissue bacteria infection. Int. J. Biol. Macromol. (2020). https://doi.org/10.1016/j.ijbiomac.2020.11.075
  196. S. Obuobi, K. Julin, E.G.A. Fredheim, M. Johannessen, N. Skalko-Basnet, Liposomal delivery of antibiotic loaded nucleic acid nanogels with enhanced drug loading and synergistic anti-inflammatory activity against S. aureus intracellular infections. J. Control. Release 324(1), 620–632 (2020). https://doi.org/10.1016/j.jconrel.2020.06.002
  197. E. Teirlinck, A. Barras, J. Liu, J.C. Fraire, T. Lajunen et al., Exploring light-sensitive nanocarriers for simultaneous triggered antibiotic release and disruption of biofilms upon generation of laser-induced vapor nanobubbles. Pharmaceutics 11(5), 201 (2019). https://doi.org/10.3390/pharmaceutics11050201
  198. K.A. Vandera, P. Picconi, M. Valero, G. Gonzalez-Gaitano, A. Woods et al., Antibiotic-in-cyclodextrin-in-liposomes: formulation development and interactions with model bacterial membranes. Mol. Pharmaceut. 17(7), 2354–2369 (2020). https://doi.org/10.1021/acs.molpharmaceut.0c00096
  199. X. Pang, Q. Xiao, Y. Cheng, E. Ren, L. Lian et al., Bacteria-responsive nanoliposomes as smart sonotheranostics for multidrug resistant bacterial infections. ACS Nano 13(2), 2427–2438 (2019). https://doi.org/10.1021/acsnano.8b09336
  200. Y. Wu, Z. Song, H. Wang, H. Han, Endogenous stimulus-powered antibiotic release from nanoreactors for a combination therapy of bacterial infections. Nat. Commun. 10(1), 4464 (2019). https://doi.org/10.1038/s41467-019-12233-2
  201. G. Yang, S. Chen, J. Zhang, Bioinspired and biomimetic nanotherapies for the treatment of infectious diseases. Front. Pharmacol. 10(1), 751 (2019). https://doi.org/10.3389/fphar.2019.00751
  202. W. Gao, L. Zhang, Coating nanoparticles with cell membranes for targeted drug delivery. J. Drug Target. 23(7–8), 619–626 (2015). https://doi.org/10.3109/1061186X.2015.1052074
  203. W. Huang, Q. Zhang, W. Li, M. Yuan, J. Zhou et al., Development of novel nanoantibiotics using an outer membrane vesicle-based drug efflux mechanism. J. Control. Release 317(1), 1–22 (2020). https://doi.org/10.1016/j.jconrel.2019.11.017
  204. F. Gao, L. Xu, B. Yang, F. Fan, L. Yang, Kill the real with the fake: Eliminate intracellular staphylococcus aureus using nanoparticle coated with its extracellular vesicle membrane as active-targeting drug carrier. ACS Infect. Dis. 5(2), 218–227 (2019). https://doi.org/10.1021/acsinfecdis.8b00212
  205. R. Pascale, M. Giannella, M. Bartoletti, P. Viale, F. Pea, Use of meropenem in treating carbapenem-resistant enterobacteriaceae infections. Expert Rev. Anti-Infe. Therapy 17(10), 819–827 (2019). https://doi.org/10.1080/14787210.2019.1673731
  206. F.M. Brunkhorst, M. Oppert, G. Marx, F. Bloos, K. Ludewig et al., Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA 307(22), 2390–2399 (2012). https://doi.org/10.1001/jama.2012.5833
  207. J.A. Roberts, M.H. Abdul-Aziz, J.S. Davis, J.M. Dulhunty, M.O. Cotta et al., Continuous versus intermittent b-lactam infusion in severe sepsis: a meta-analysis of individual patient data from randomized trials. Am. J. Resp. Crit. Care 194(6), 681–691 (2016). https://doi.org/10.1164/rccm.201601-0024OC
  208. P.N.A. Harris, P.A. Tambyah, D.C. Lye, Y. Mo, T.H. Lee et al., N. the Australasian Society for Infectious Disease Clinical Research. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with e coli or klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: A randomized clinical trial. Jama 320(10), 984–994 (2018). https://doi.org/10.1001/jama.2018.12163
  209. A. Abdelkader, M.A. El-Mokhtar, O. Abdelkader, M.A. Hamad, M. Elsabahy et al., Ultrahigh antibacterial efficacy of meropenem-loaded chitosan nanoparticles in a septic animal model. Carbohyd. Polym. 174(1), 1041–1050 (2017). https://doi.org/10.1016/j.carbpol.2017.07.030
  210. J. Ndayishimiye, A. Popat, M. Blaskovich, J.R. Falconer, Formulation technologies and advances for oral delivery of novel nitroimidazoles and antimicrobial peptides. J. Control. Release (2020). https://doi.org/10.1016/j.jconrel.2020.05.002
  211. A.C. Saude, A.S. Ombredane, O.N. Silva, J.A. Barbosa, S.E. Moreno et al., Clavanin bacterial sepsis control using a novel methacrylate nanocarrier. Int. J. Nanomed. 9(1), 5055–5069 (2014). https://doi.org/10.2147/IJN.S66300
  212. C. Falciani, F. Zevolini, J. Brunetti, G. Riolo, R. Gracia et al., Antimicrobial peptide-loaded nanoparticles as inhalation therapy for pseudomonas aeruginosa infections. Int. J. Nanomed. 15(1), 1117–1128 (2020). https://doi.org/10.2147/IJN.S218966
  213. N. Mookherjee, M.A. Anderson, H.P. Haagsman, D.J. Davidson, Antimicrobial host defence peptides: functions and clinical potential. Nat. Rev. Drug Discov. 19(5), 311–332 (2020). https://doi.org/10.1038/s41573-019-0058-8
  214. A.J. Beevers, A.M. Dixon, Helical membrane peptides to modulate cell function. Chem. Soc. Rev. 39(6), 2146–2157 (2010). https://doi.org/10.1039/b912944h
  215. T. Ganz, Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3(9), 710–720 (2003). https://doi.org/10.1038/nri1180
  216. B.P. Lazzaro, M. Zasloff, J. Rolff, Antimicrobial peptides: application informed by evolution. Science 368(6490), 5480 (2020). https://doi.org/10.1126/science.aau5480
  217. Y. Scindia, E. Wlazlo, J. Leeds, V. Loi, J. Ledesma et al., Protective role of hepcidin in polymicrobial sepsis and acute kidney injury. Front. Pharm. 10(1), 615 (2019). https://doi.org/10.3389/fphar.2019.00615
  218. Y.H. Huang, Y.L. Yang, M.M. Tiao, H.C. Kuo, L.T. Huang et al., Hepcidin protects against lipopolysaccharide-induced liver injury in a mouse model of obstructive jaundice. Peptides 35(2), 212–217 (2012). https://doi.org/10.1016/j.peptides.2012.03.032
  219. N.H. Salzman, D. Ghosh, K.M. Huttner, Y. Patersonk, C.L. Bevins, Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature 422(6931), 522–526 (2003). https://doi.org/10.1038/nature01520
  220. E. de Leeuw, S.R. Burks, X. Li, J.P. Kao, W. Lu, Structure-dependent functional properties of human defensin 5. FEBS Lett. 581(3), 515–520 (2007). https://doi.org/10.1016/j.febslet.2006.12.036
  221. C. Wang, M. Shen, N. Gohain, W.D. Tolbert, F. Chen et al., Design of a potent antibiotic peptide based on the active region of human defensin 5. J. Med. Chem. 58(7), 3083–3093 (2015). https://doi.org/10.1021/jm501824a
  222. A. de Breij, M. Riool, R.A. Cordfunke, N. Malanovic, L. de Boer et al., The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms. Sci. Transl. Med. 10, 4044 (2018). https://doi.org/10.1126/scitranslmed.aan4044
  223. L. Liu, K. Xu, H. Wang, P.K. Tan, W. Fan et al., Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat. Nanotechnol. 4(7), 457–463 (2009). https://doi.org/10.1038/nnano.2009.153
  224. B. Mathew, R. Nagaraj, Antimicrobial activity of human alpha-defensin 5 and its linear analogs: N-terminal fatty acylation results in enhanced antimicrobial activity of the linear analogs. Peptides 71, 128–140 (2015). https://doi.org/10.1016/j.peptides.2015.07.009
  225. J.J. Lee, K.J. Jeong, M. Hashimoto, A.H. Kwon, A. Rwei et al., Synthetic ligand-coated magnetic nanoparticles for microfluidic bacterial separation from blood. Nano Lett. 14(1), 1–5 (2014). https://doi.org/10.1021/nl3047305
  226. X. Hou, X. Zhang, W. Zhao, C. Zeng, B. Deng et al., Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. Nat. Nanotechnol. 15(1), 41–46 (2020). https://doi.org/10.1038/s41565-019-0600-1
  227. J. Zhou, G. Yu, F. Huang, Supramolecular chemotherapy based on host-guest molecular recognition: a novel strategy in the battle against cancer with a bright future. Chem. Soc. Rev. 46(22), 7021–7053 (2017). https://doi.org/10.1039/c6cs00898d
  228. I.K. Herrmann, M. Urner, S. Graf, C.M. Schumacher, B. Roth-Z’graggen et al., Endotoxin removal by magnetic separation-based blood purification. Adv. Healthc. Mater. 2(6), 829–835 (2013). https://doi.org/10.1002/adhm.201200358
  229. T. Liu, B. Xiao, F. Xiang, J. Tan, Z. Chen et al., Ultrasmall copper-based nanoparticles for reactive oxygen species scavenging and alleviation of inflammation related diseases. Nat. Commun. 11(1), 2788 (2020). https://doi.org/10.1038/s41467-020-16544-7
  230. M. Soh, D.W. Kang, H.G. Jeong, D. Kim, D.Y. Kim et al., Ceria-zirconia nanoparticles as an enhanced multi-antioxidant for sepsis treatment. Angew. Chem. Int. Ed. 56(38), 11399–11403 (2017). https://doi.org/10.1002/anie.201704904
  231. V. Selvaraj, N.D. Manne, R. Arvapalli, K.M. Rice, G. Nandyala et al., Effect of cerium oxide nanoparticles on sepsis induced mortality and NF-kappaB signaling in cultured macrophages. Nanomedicine 10(8), 1275–1288 (2015). https://doi.org/10.2217/nnm.14.205
  232. S. Asano, R. Arvapalli, N.D. Manne, M. Maheshwari, B. Ma et al., Cerium oxide nanoparticle treatment ameliorates peritonitis-induced diaphragm dysfunction. Int. J. Nanomed. 10(1), 6215–6225 (2015). https://doi.org/10.2147/IJN.S89783
  233. S.K. Rajendrakumar, V. Revuri, M. Samidurai, A. Mohapatra, J.H. Lee et al., Peroxidase-mimicking nanoassembly mitigates lipopolysaccharide-induced endotoxemia and cognitive damage in the brain by impeding inflammatory signaling in macrophages. Nano Lett. 18(10), 6417–6426 (2018). https://doi.org/10.1021/acs.nanolett.8b02785
  234. S. Thamphiwatana, P. Angsantikul, T. Escajadillo, Q. Zhang, J. Olson et al., Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management. Proc. Natl. Acad. Sci. USA 114(43), 11488–11493 (2017). https://doi.org/10.1073/pnas.1714267114
  235. R. Molinaro, A. Pasto, C. Corbo, F. Taraballi, F. Giordano et al., Macrophage-derived nanovesicles exert intrinsic anti-inflammatory properties and prolong survival in sepsis through a direct interaction with macrophages. Nanoscale 11(28), 13576–13586 (2019). https://doi.org/10.1039/c9nr04253a
  236. S. Shen, F. Han, A. Yuan, L. Wu, J. Cao et al., Engineered nanoparticles disguised as macrophages for trapping lipopolysaccharide and preventing endotoxemia. Biomaterials 189(1), 60–68 (2019). https://doi.org/10.1016/j.biomaterials.2018.10.029
  237. V. Chhabria, S. Beeton, Development of nanosponges from erythrocyte ghosts for removal of streptolysin-o from mammalian blood. Nanomedicine 11(21), 2797–2807 (2016). https://doi.org/10.2217/nnm-2016-0180
  238. Y. Chen, Y. Zhang, M. Chen, J. Zhuang, R.H. Fang et al., Biomimetic nanosponges suppress in vivo lethality induced by the whole secreted proteins of pathogenic bacteria. Small 15(6), e1804994 (2019). https://doi.org/10.1002/smll.201804994
  239. G. Kibria, E.K. Ramos, Y. Wan, D.R. Gius, H. Liu, Exosomes as a drug delivery system in cancer therapy: potential and challenges. Mol. Pharmaceut. 15(9), 3625–3633 (2018). https://doi.org/10.1021/acs.molpharmaceut.8b00277
  240. N. Terrasini, V. Lionetti, Exosomes in critical illness. Crit. Care Med. 45(6), 1054–1060 (2017). https://doi.org/10.1097/CCM.0000000000002328
  241. J. Gao, S. Wang, Z. Wang, High yield, scalable and remotely drug-loaded neutrophil-derived extracellular vesicles (EVS) for anti-inflammation therapy. Biomaterials 135, 62–73 (2017). https://doi.org/10.1016/j.biomaterials.2017.05.003
  242. K.S. Park, K. Svennerholm, G.V. Shelke, E. Bandeira, C. Lasser et al., Mesenchymal stromal cell-derived nanovesicles ameliorate bacterial outer membrane vesicle-induced sepsis via il-10. Stem Cell Res. Ther. 10(1), 231 (2019). https://doi.org/10.1186/s13287-019-1352-4
  243. W. Lee, J. Seo, S. Kwak, E.J. Park, D.H. Na et al., A double-chambered protein nanocage loaded with thrombin receptor agonist peptide (TRAP) and gamma-carboxyglutamic acid of protein c (PC-Gla) for sepsis treatment. Adv. Mater. 27(42), 6637–6643 (2015). https://doi.org/10.1002/adma.201503093
  244. C.Y. Zhang, X. Dong, J. Gao, W. Lin, Z. Liu et al., Nanoparticle-induced neutrophil apoptosis increasessurvival in sepsis and alleviates neurologicaldamage in stroke. Sci. Adv. 5, 7964 (2019). https://doi.org/10.1126/sciadv.aax7964
  245. Y. Xin, M. Huang, W.W. Guo, Q. Huang, L.Z. Zhang et al., Nano-based delivery of RNAI in cancer therapy. Mol. Cancer 16(1), 134 (2017). https://doi.org/10.1186/s12943-017-0683-y
  246. H. He, N. Zheng, Z. Song, K.H. Kim, C. Yao et al., Suppression of hepatic inflammation via systemic sirna delivery by membrane-disruptive and endosomolytic helical polypeptide hybrid nanoparticles. ACS Nano 10(2), 1859–1870 (2016). https://doi.org/10.1021/acsnano.5b05470
  247. R. Penalva, C.J. Gonzalez-Navarro, C. Gamazo, I. Esparza, J.M. Irache, Zein nanoparticles for oral delivery of quercetin: pharmacokinetic studies and preventive anti-inflammatory effects in a mouse model of endotoxemia. Nanomed. Nanotechnol. 13(1), 103–110 (2017). https://doi.org/10.1016/j.nano.2016.08.033
  248. S. Mura, J. Nicolas, P. Couvreur, Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 12(11), 991–1003 (2013). https://doi.org/10.1038/nmat3776
  249. L.M. Casey, S. Kakade, J.T. Decker, J.A. Rose, K. Deans et al., Cargo-less nanoparticles program innate immune cell responses to toll-like receptor activation. Biomaterials 218, 119333 (2019). https://doi.org/10.1016/j.biomaterials.2019.119333
  250. S. Spence, M.K. Greene, F. Fay, E. Hams, S.P. Saunders et al., Targeting siglecs with a sialic acid–decoratednanoparticle abrogates inflammation. Sci. Transl. Med. 7(303), 303ra140 (2015). https://doi.org/10.1126/scitranslmed.aab3459
  251. G. Li-Volti, T. Musumeci, R. Pignatello, P. Murabito, I. Barbagallo et al., Antioxidant potential of different melatonin-loaded nanomedicines in an experimental model of sepsis. Exp. Biol. Med. 237(6), 670–677 (2012). https://doi.org/10.1258/ebm.2012.011425
  252. S. Zhang, J. Ermann, M.D. Succi, A. Zhou, M.J. Hamilton et al., An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease. Sci. Transl. Med. 7(300), 300128 (2015). https://doi.org/10.1126/scitranslmed.aaa5657
  253. N. Joshi, J. Yan, S. Levy, S. Bhagchandani, K.V. Slaughter et al., Towards an arthritis flare-responsive drug delivery system. Nat. Commun. 9(1), 1275 (2018). https://doi.org/10.1038/s41467-018-03691-1
  254. S.B. Lim, I. Rubinstein, R.T. Sadikot, J.E. Artwohl, H. Onyuksel, A novel peptide nanomedicine against acute lung injury: Glp-1 in phospholipid micelles. Pharm. Res. 28(3), 662–672 (2011). https://doi.org/10.1007/s11095-010-0322-4
  255. M.C. Ferrer, V.V. Shuvaev, B.J. Zern, R.J. Composto, V.R. Muzykantov et al., ICAM-1 targeted nanogels loaded with dexamethasone alleviate pulmonary inflammation. PLoS ONE 9(7), e102329 (2014). https://doi.org/10.1371/journal.pone.0102329
  256. E.B. Okeke, C. Louttit, C. Fry, A.H. Najafabadi, K. Han et al., Inhibition of neutrophil elastase prevents neutrophil extracellular trap formation and rescues mice from endotoxic shock. Biomaterials 238(1), 119836 (2020). https://doi.org/10.1016/j.biomaterials.2020.119836
  257. C.Y. Zhang, J. Gao, Z. Wang, Bioresponsive nanoparticles targeted to infectious microenvironments for sepsis management. Adv. Mater. 30(43), e1803618 (2018). https://doi.org/10.1002/adma.201803618
  258. Y. Yang, Y. Ding, B. Fan, Y. Wang, Z. Mao et al., Inflammation-targeting polymeric nanoparticles deliver sparfloxacin and tacrolimus for combating acute lung sepsis. J. Control. Release 321, 463–474 (2020). https://doi.org/10.1016/j.jconrel.2020.02.030
  259. W. Lee, E.J. Park, G. Min, J. Choi, D.H. Na et al., Dual functioned pegylated phospholipid micelles containing cationic antimicrobial decapeptide for treating sepsis. Theranostics 7(15), 3759–3767 (2017). https://doi.org/10.7150/thno.20734
  260. L. Tang, Z. Wang, Q. Mu, Z. Yu, O. Jacobson et al., Targeting neutrophils for enhanced cancer theranostics. Adv. Mater. 32(33), e2002739 (2020). https://doi.org/10.1002/adma.202002739
  261. S. Wang, J. Lv, S. Meng, J. Tang, L. Nie, Recent advances in nanotheranostics for treat-to-target of rheumatoid arthritis. Adv. Healthc. Mater. 9(6), e1901541 (2020). https://doi.org/10.1002/adhm.201901541
  262. B. Ma, H. Xu, W. Zhuang, Y. Wang, G. Li et al., Reactive oxygen species responsive theranostic nanoplatform for two-photon aggregation-induced emission imaging and therapy of acute and chronic inflammation. ACS Nano 14(5), 5862–5873 (2020). https://doi.org/10.1021/acsnano.0c01012
  263. E.V. Fuior, C.A. Mocanu, M. Deleanu, G. Voicu, M. Anghelache et al., Evaluation of VCAM-1 targeted naringenin/indocyanine green-loaded lipid nanoemulsions as theranostic nanoplatforms in inflammation. Pharmaceutics 12(11), 1066 (2020). https://doi.org/10.3390/pharmaceutics12111066
  264. D. Mao, F. Hu, S. Ji, W. Wu, D. Ding et al., Metal-organic-framework-assisted in vivo bacterial metabolic labeling and precise antibacterial therapy. Adv. Mater. 30(18), e1706831 (2018). https://doi.org/10.1002/adma.201706831
  265. C. Shi, X. Wang, L. Wang, Q. Meng, D. Guo et al., A nanotrap improves survival in severe sepsis by attenuating hyperinflammation. Nat. Commun. 11(1), 3384 (2020). https://doi.org/10.1038/s41467-020-17153-0
  266. M.I. Setyawati, C.Y. Tay, D. Docter, R.H. Stauber, D.T. Leong, Understanding and exploiting nanoparticles’ intimacy with the blood vessel and blood. Chem. Soc. Rev. 44(22), 8174–8199 (2015). https://doi.org/10.1039/c5cs00499c
  267. M. Wang, J. Li, S. Dong, X. Cai, A. Simaiti et al., Silica nanoparticles induce lung inflammation in mice via ROS/PARP/TRPM2 signaling-mediated lysosome impairment and autophagy dysfunction. Part. Fibre Toxicol. 17(1), 23 (2020). https://doi.org/10.1186/s12989-020-00353-3
Read More
Author biographies are not available.
Download this PDF file
PDF
Statistic
Read Counter : 9443 Download : 7140

Most read articles by the same author(s)